BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 119 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,760 | -64.3% | 1,015 | 0.0% | 0.00% | -100.0% |
| Q1 2023 | $18,940 | -32.4% | 1,015 | -22.2% | 0.00% | 0.0% |
| Q4 2022 | $28,031 | +81.7% | 1,305 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $15,425 | -10.5% | 1,305 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $17,226 | -36.9% | 1,305 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $27,288 | -72.5% | 1,305 | -73.3% | 0.00% | 0.0% |
| Q4 2021 | $99,251 | -33.0% | 4,882 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $148,169 | +28.3% | 4,882 | +22.9% | 0.00% | 0.0% |
| Q2 2021 | $115,455 | -21.3% | 3,973 | +16.8% | 0.00% | 0.0% |
| Q1 2021 | $146,787 | -6.6% | 3,401 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $157,126 | +6.5% | 3,401 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $147,467 | -18.2% | 3,401 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $180,287 | – | 3,401 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |